Loading news...
Nuvation Bio (NYSE: NUVB - Get Free Report) and MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Risk and Volatility Nuvation Bio has a beta
Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nuvation Bio (NUVB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI® (taletrectinib) and provided a 2026 outlook ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Preliminary Fourth Quarter and Full Year 2025 Financial Results and IBTROZI Commercial Results In the.
NEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agree.
Cwm LLC increased its position in Nuvation Bio Inc. (NYSE: NUVB) by 169.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 102,328 shares of the company's stock after acquiring an additional 64,365 shares during the period. Cwm LLC's
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, CA. A live webcast of the presentation will be available on the Investor Relations section o.
The consensus price target hints at a 32.1% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Shares of Nuvation Bio Inc. (NYSE: NUVB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating on
The consensus price target hints at a 25.1% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection, a recombinant anti-IGF-1R antibody), Limertinib (EGFR TKI), Dupert® (fulzerasib, KRAS G12C inhibitor), DOVBLERON® (taletrectinib, ROS1 inhibitor), Retsevmo® (selpercatinib, RET inhibitor), and Jaypirca® (pirtobrutinib, BTK inhibitor).
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology. “Until.
Nuvation Bio (NUVB) is downgraded from Buy to Hold as its stock price now reflects improved Ibtrozi rollout visibility and strong fundamentals. Ibtrozi's commercial launch is robust, with early patient uptake and revenue run-rate supporting a $300–$600 million forward revenue estimate for NUVB. Despite a solid balance sheet and pipeline potential, NUVB's current valuation no longer offers the deep discount that justified aggressive buying at lower prices.
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL.
Nuvation Bio Inc. ( NUVB ) Jefferies London Healthcare Conference 2025 November 19, 2025 10:00 AM EST Company Participants David Hung - Founder, President, CEO & Chairman Philippe Sauvage - CFO & Principal Financial Officer Conference Call Participants Farzin Haque - Jefferies LLC, Research Division Presentation Farzin Haque Jefferies LLC, Research Division Hi, everyone. My name is Farzin Haque.
Nuvation Bio is demonstrating strong early commercial success with Ibtrozi, its newly FDA-approved therapy for ROS1-positive non-small cell lung cancer. NUVB reported 204 new patients for Ibtrozi in the latest quarter, supporting a robust revenue trajectory and validating the product's market potential. A conservative revenue projection supports NUVB's current market cap. The value of ex-US market rights of Ibtrozi, together with the rest of its product pipelines, provides further hedges.
Nuvation Bio Inc. (NYSE: NUVB - Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 8,120 call options on the company. This represents an increase of 212% compared to the typical volume of 2,599 call options. Insider Buying and Selling at Nuvation Bio In other news, insider Gary Hattersley sold 100,000 shares of
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.